The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis
Journal of Viral Hepatitis · 2023
DOI: 10.1111/jvh.13814 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Ira M Jacobson und 11 weiteren Autor:innen. Beteiligte Einrichtung: NYU Langone Health, New York, New York, USA. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
To evaluate the safety and tolerability of the fixed‐dose, single‐tablet regimen sofosbuvir/velpatasvir (SOF/VEL) for the treatment of hepatitis C virus (HCV) infection in three Phase 3 studies in patients with and without compensated cirrhosis. Data from three registrational trials (ASTRAL‐1, NCT02201940; ASTRAL‐2, NCT02220998; ASTRAL‐3, NCT02201953) were pooled by treatment regimen. Researchers assessed treatment‐emergent adverse events (TEAEs) and laboratory abnormalities in patients randomized to SOF/VEL or placebo for 12 weeks in ASTRAL‐1 and SOF/VEL for 12 weeks in ASTRAL‐2 and ASTRAL‐3. Overall, 1035 patients were treated with SOF/VEL, and 116 patients received placebo. Rates of any TEAE were generally similar between patients receiving SOF/VEL (79.4%) and those receiving placebo (76.7%). The majority of TEAEs were mild to moderate, with 23 (2.2%) treatment‐emergent serious AEs in patients treated with SOF/VEL. Of these treatment‐emergent serious AEs, none led to premature study discontinuation, nor were they considered related to treatment. Presence of compensated cirrhosis, greater age and mild renal impairment did not impact incidence or severity of TEAEs with SOF/VEL treatment. The most common TEAEs (incidence ≥10%) were headache, fatigue, nausea and nasopharyngitis in patients receiving SOF/VEL; similar rates were observed in placebo‐treated patients. Three deaths (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NYU Langone Health, New York, New York, USA.
- Campus Stuivenberg, Antwerp, Belgium.
- Centre Hospitalier Universitaire de Lille, Universite Nord de France, Lille, France.
- Institute for Digestive Health and Liver Disease, Baltimore, Maryland, USA.
- NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals NHS Trust and The University of Nottingham, Queen's Medical Centre Campus, Nottingham, UK.
- Helios Klinikum Niederberg, Velbert, Germany.
Förderung
- Gilead Sciences
Zitieren
APA
Jacobson, I. M., Bourgeois, S., Mathurin, P., Thuluvath, P., Ryder, S. D., Gerken, G., Hernandez, C., Vanstraelen, K., Scherbakovsky, S., Osinusi, A., Tedesco, D., & Foster, G. R. (2023). The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13814
Vancouver
Jacobson IM, Bourgeois S, Mathurin P, Thuluvath P, Ryder SD, Gerken G, et al. The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis. Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13814
BibTeX
@article{Jacobson2023,
author = {Jacobson, Ira M and Bourgeois, Stefan and Mathurin, Phillipe and Thuluvath, Paul and Ryder, Stephen D and Gerken, Guido and Hernandez, Candido and Vanstraelen, Kim and Scherbakovsky, Stacey and Osinusi, Anu and Tedesco, Dana and Foster, Graham R},
title = {The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis},
journal = {Journal of Viral Hepatitis},
year = {2023},
doi = {10.1111/jvh.13814}
}
EUVIMED